Subscriber query about last week's Small Cap Stock Tip19.05.2014

One of our subscribers asked a good question about why Medical Development's Penthrox product hadn't been commercialised offshort previously. Below is our response:

I spoke to the managing director John Sharman about this and he told me that commercialising Penthrox was never a company focus and it had never invested in the regulatory and clinical documentation that was needed to get approved elsewhere. It’s taken 4 years and bout $7m to get to the position of approval in Europe, and after this the US.

Penthrox is based on the drug Methroxyflurane, which was initially used as an anaesthetic in the 1960s but wasn’t effective. Medical Developments pioneered its use as an analgesic, which means it relieves pain, like morphine, but it’s meant to have less side effects.

If you have any queries, please feel free to contact us via email or phone on 02 9331 1999.

Best wishes

Richard Hemming

About the Author

Richard Hemming

Investment analyst and Editor of Under the Radar Report

Start Your 30 day free trial today

Do you want to get access to our weekly reports?
Leave your details and get an instant access.

As Seen In